苯巴那酯有几种规格?多少钱?

Phenobarnate is a new type of anti-epileptic drug. Through its unique dual mechanism-inhibiting voltage-gated sodium channels and enhancing the inhibitory signaling of CABA receptors, it can effectively reduce the abnormal discharge of neurons and thereby control epileptic seizures. This drug is produced by the Italian ANGELINI company and is available in a variety of specifications. The price varies depending on the specifications. When using it, special attention must be paid to its impact on the QT interval and adverse reactions to the nervous system.

Phenobanate is available in several specifications

In order to meet the treatment needs of different patients, a variety of dosage specifications are provided. These specifications are designed taking into account the flexibility of medication and the continuity of treatment.

Basic dosage specifications

The drug is available in three basic tablet specifications: 12.5mg, 25mg and 50mg. The 12.5 mg strength is commonly used in the initial treatment phase or in pediatric patients, while the 25 mg and 50 mg strengths are suitable for maintenance treatment in most adult patients.

Combined packaging specifications

To facilitate dosage adjustment, the manufacturer has launched a 12.5 mg + 25 mg combination package, including 28 pills. This packaging design allows doctors to flexibly adjust the dosage according to patient response.

Large format packaging

For patients requiring long-term treatment, large packaging of 84 capsules of 50mg and 200mg is provided. Large packaging is more suitable for long-term medication for stable patients and can reduce the frequency of drug purchase.

The setting of multiple specifications provides flexibility for clinical medication. Doctors can choose the most appropriate specifications and packaging according to the patient's individual conditions.

How much does Phenobarnate cost in different specifications?

As an imported original drug, its price is affected by factors such as specifications and packaging quantity. Knowing the price of each specification can help with treatment planning.

Small size packaging price

The price of 12.5mg+25mg*28 tablets is about US$206, and the price of 50mg*14 tablets is about US$117. The small size is suitable for use in the initial treatment or dose discovery phase.

Medium size price

The price of 50mg*28 capsules is about US$231. This mid-range strength is suitable for mid-term treatment phases with established dosing.

Large size packaging price

50mg*84 capsules and 200mg*84 capsules are both priced at approximately US$521. Large sizes are more economical and suitable for long-term maintenance treatment.

The price difference is mainly due to packaging specifications and drug content. Patients can choose appropriate specifications according to the stage of treatment and economic situation.

Precautions for Phenomenate

When using Phenomenate, special attention should be paid to its impact on cardiac electrophysiology and adverse reactions to the nervous system.

Effects on QT interval

This drug will shorten the QT interval and is contraindicated in patients with familial short QT syndrome. Caution should be exercised when combined with other drugs that shorten the QT interval as they may increase the risk of arrhythmias.

Mental health monitoring

Suicidal tendencies and behavioral changes need to be closely monitored during medication. Patients and family members should pay attention to abnormal changes in mood or behavior.

Nervous system reactions

Common adverse reactions such as drowsiness and fatigue. Avoid driving or operating dangerous machinery while taking the drug until the individual's response to the drug is known.

Precautions for discontinuing medication

The dosage should be gradually reduced and discontinued. Sudden discontinuation may increase the risk of seizures. Consider rapid discontinuation only in the case of serious adverse reactions.

Strictly following these precautions can maximize the effectiveness of treatment while reducing the risks of medication. Patients should undergo regular follow-up visits and provide timely feedback on medication response.